GlassScriptPhysician profile
Sara F Barber
NPI 1740210541
$3,042.19
in general payments reported to CMS, 2019-2025
21 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $740 · 2023: $859 · 2024: $740 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $541.44 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.22 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $235.20 | 2021-2025 | Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $194.16 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $161.93 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $151.11 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $119.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.43 | 2021-2025 | Trintellix |
| Tempus Ai, INC | $97.07 | 2024 | |
| Axsome Therapeutics, INC. | $61.17 | 2022 | |
| Corium, LLC | $60.64 | 2022 | |
| Lundbeck LLC | $47.24 | 2023 | Rexulti |
| Eisai INC. | $36.19 | 2021 | |
| Merck Sharp & Dohme LLC | $32.87 | 2021-2023 | Belsomra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $23.45 | 2023 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $17.07 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $16.52 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.90 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.61 | 2023 | Qelbree |
| Glaxosmithkline, LLC. | $13.07 | 2024 | Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.